Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livionex for dental plaque in pediatric HSCT
NCT02617407Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Jul 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Livionex CVI Topical Treatment in dental plaque and gingivitis (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Adherence to oral hygiene at 7 days, Plaque index score at 44 days and 2 more. Started Jul 2016; status: completed.
02
Drugs
Livionex CVI Topical Treatment
03
Conditions
dental plaquegingivitis
Beyond the preview
Go deeper on NCT02617407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617407.